Last update Dec. 2, 2022


Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a cholecystokinin antagonist with an inhibitory effect on gastric secretion. Oral, intramuscular or intravenous administration in the treatment of peptic ulcer and other gastrointestinal disorders.

At the date of the last update we did not find any published data on its excretion in breast milk.

The absence of known pharmacokinetic data does not allow the prediction of its possible excretion in breast milk.

Cholecystocinin has been found in the brain and related to development of maternal behaviour in mammals.

Product with very few and/or very old bibliographic references, marketed in few countries.

Safer known alternatives are preferable during breastfeeding, especially during the neonatal period and in case of prematurity.


  • Famotidine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Nizatidine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Omeprazole ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Sucralfate ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Xylamide is also known as Proglumide.

Xylamide in other languages or writings:


Main tradenames from several countries containing Xylamide in its composition:


Variable Value Unit
Molecular weight 334 daltons
pKa 4.42 -
Tmax 1 hours
3 hours


  1. Hsu CC, Bansal S, Cao H, Smith CI, He AR, Gay MD, Li Y, Cheema A, Smith JP. Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. Pharmaceutics. 2022 Mar 12;14(3). pii: 627. Abstract Full text (link to original source)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM